Belite Bio Inc (BLTE)
NASDAQ: BLTE
· Real-Time Price · USD
60.06
-2.08 (-3.35%)
At close: Jun 13, 2025, 3:59 PM
59.55
-0.85%
After-hours: Jun 13, 2025, 04:00 PM EDT
-3.35% (1D)
| Bid | 58.4 |
| Market Cap | 1.95B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -36.14M |
| EPS (ttm) | -1.36 |
| PE Ratio (ttm) | -44.16 |
| Forward PE | -38.63 |
| Analyst | Buy |
| Ask | 62.89 |
| Volume | 19,783 |
| Avg. Volume (20D) | 33,273 |
| Open | 61.21 |
| Previous Close | 62.14 |
| Day's Range | 59.51 - 61.45 |
| 52-Week Range | 43.70 - 86.53 |
| Beta | -1.45 |
About BLTE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BLTE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BLTE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+3.83%
Belite Bio shares are trading higher after the com...
Unlock content with
Pro Subscription
4 months ago
+3.58%
Belite Bio shares are trading higher after Benchmark raised its price target on the stock from $57 to $79.
1 month ago · seekingalpha.com
Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study ReadoutBelite Bio's lead drug, Tinlarebant, shows promise in rare eye diseases, but pivotal data and regulatory approval remain at least 18 months away in my view. The DRAGON study's interim analysis is enco...
